Real-world data show abbott's freestyle libre® systems and glp-1 medicines work better together for people with type 2 diabetes

Data analyses show that people with type 2 diabetes using glp-1 medicines saw a significant improvement in their hba1c after adding freestyle libre technology to their regimen better hba1c results were achieved irrespective of glp-1 duration, glp-1 type, or insulin therapy type freestyle libre systems help people adhere to diabetes treatment plans and support positive behavior changes by providing real-time data that shows how food, activity and medication can impact a person's glucose levels abbott park, ill., march 6, 2024 /prnewswire/ -- abbott (nyse: abt) today announced new data from two real-world studies1, 2 showing people with type 2 diabetes using glp-1 medicines and freestyle libre technology together had greater improvement in their hba1c when compared to those treated with glp-1 medicines only.
ABT Ratings Summary
ABT Quant Ranking